September 29, 2009
Article
The following company announcements were made at the 2009 World Conference on Lung Cancer in San Francisco.
September 29, 2009
Article
In response to the article “Oncology takes blame for rising healthcare cost” (page 1, July 2009), I would like to direct Oncology News International readers to two articles on the “Win-Win” initiative. The full text articles are available online for free at:
September 29, 2009
Article
In patients with resected pancreatic cancer, adjuvant cisplatin, 5-FU, and interferon chemoradiation produces a median survival of 27 months, according to initial results of the ACOSOG Z05031 trial. However, nearly all patients experience grade 3 or 4 toxicities.
September 29, 2009
Article
Low tumor levels of the MSH2 protein predict long-term response to cisplatin-based chemotherapy in patients with resected non-small-cell lung cancer, according to an analysis from the International Adjuvant Lung Trial.
September 29, 2009
Article
The Association of Community Cancer Centers recently surveyed its members and found a universal request for assistance in developing prostate cancer care programs. The ACCC responded by setting up pilot programs in the U.S. that focus on the following areas:
September 29, 2009
Article
Although preoperative radiotherapy has been shown to improve recurrence and mortality rates in patients with rectal cancer, a quality-of-life analysis by the same researchers suggests that male sexual dysfunction and fecal incontinence may be the trade-offs for those improved outcomes
September 28, 2009
Article
Researchers in Seoul, Korea, found early-phase contrast-enhanced CT useful for differentiating pulmonary metastases from hepatocellular carcinoma and primary lung cancer. They specifically measured the attenuations of pulmonary nodules on the CT scans.
September 28, 2009
Article
Marcia Prenguber, ND, FABNO, director of integrative care at Goshen Center for Cancer Care in Indiana, said more than 75% of patients use complementary and alternative medicine, yet remain reluctant to tell their oncologists about it. Dr. Prenguber said she does not consider complementary medicine as an alternative to standard treatment, but as a way to tailor healing to the individual.
September 28, 2009
Article
Harmit Singh Malik, PhD, and Ulrike “Riki” Peters, PhD, both based at the Fred Hutchinson Cancer Research Center in Seattle, received the 2008 Presidential Early Career Award for Scientists and Engineers. Dr. Malik is an evolutionary biologist.
September 28, 2009
Article
BERLIN-Panitumumab (Vectibix), in combination with FOLFIRI as second-line treatment, significantly improved progression-free survival compared to FOLFIRI alone in patients with KRAS wild-type metastatic colorectal cancer, according to study results that will be presented at ESMO 2009 (see Table). However median overall survival did not achieve statistical significance in the study arm.
September 24, 2009
Article
In about 30% of U.S. women who receive a diagnosis of early breast cancer, the cancer will progress to metastatic disease, but in the developing world, most cancer is initially diagnosed at an advanced stage, said William Gradishar, MD, director of medical breast oncology at the Robert H. Lurie Comprehensive Cancer Center, at Northwestern University, Chicago.
September 24, 2009
Article
Bevacizumab (Avastin) alone or in combination with irinotecan, was well tolerated and active in recurrent glioblastoma, according to phase II trial results. The multicenter, open-label, noncomparative trial evaluated 167 patients randomly assigned to receive bevacizumab (10 mg/kg) alone or in combination with irinotecan (340 mg/m2 or 125 mg/m2), with or without concomitant enzyme-inducing antiepileptic drugs, respectively, once every two weeks.
September 23, 2009
Article
SAN FRANCISCO-Chemotherapy before surgery for early-stage, non-small-cell lung cancer led to moderately higher survival rates than surgery alone, but not enough to reach statistical significance, according to follow-up analysis of the European NATCH trial. However, the researchers did note that patients were more likely to finish the prescribed chemotherapy course when treatment was given preoperatively.
September 23, 2009
Article
SAN FRANCISCO-Th e new international standards for lung cancer staging and how they pertain to imaging sent sparks flying during a plenary session at the 2009 World Conference on Lung Cancer.
September 23, 2009
Article
Thanks to the tireless efforts of the breast cancer community, October and breast cancer are tightly bound with the ubiquitous pink ribbon. But the awareness campaign places a heavy emphasis on prevention, detection, and early diagnosis. For women with metastatic breast cancer, there is a sense that the “pink parade” has intentionally passed them by even though an estimated 465,000 annual deaths from breast cancer worldwide occur because of metastatic disease.
September 22, 2009
Article
The risks associated with neoadjuvant hormonal therapy may outweigh the benefits of its use in conjunction with brachytherapy in some older men with prostate cancer, according to research from the radiation oncology program at Boston’s Harvard Medical School.
September 22, 2009
Article
Biopharmaceutical company Micromet closed $80.5 million in funding last month after a public offering of 14 million shares of common stock. Earlier in the year, the company raised $40 million.
September 22, 2009
Article
More than a decade has passed since the FDA approved the first pill to fight cancer. Designed to battle metastatic colorectal cancer, capecitabine (Xeloda) marked a significant change in chemotherapy, untethering some cancer patients from office-based intravenous drug infusions. Other such drugs have since been commercially released, including temozolomide (Temodar) and imatinib (Gleevec), but the reimbursement system in this country has failed to keep up.
September 22, 2009
Article
With the availability of newer drugs for treating multiple myeloma, such as proteosome inhibitors and immunomodulatory drugs (IMiDs), outcomes and depth of response are steadily improving. These developments have led to a debate about whether high-dose chemotherapy and autologous stem cell transplant should still be considered first-line therapy or whether newer drug regimens should replace transplant.
September 22, 2009
Article
ORLANDO-Whom to treat vs whom not to treat remains a major dilemma in prostate cancer care, but distinguishing men who will benefit from treatment from those who will not is not a clear-cut prospect, according to a speaker at the 2009 ASCO Genitourinary Cancers Symposium.
September 22, 2009
Article
More than a million additional cases of prostate cancer have been diagnosed and treated for prostate cancer over the last 20 years because of PSA screening, especially in younger men, according to the results of a SEER database analysis. The authors of this latest strike against screening claimed that most of this excess incidence represents overdiagnosis.
September 21, 2009
Article
Patients with unresectable stage III or IV melanoma taking ipilimumab and the oral steroid budesonide to reduce side effects did not have less diarrhea, according to results of a phase II trial.
September 21, 2009
Article
The NCCN Clinical Practice Guidelines in Oncology for the Prevention and Treatment of Cancer-Related Infections has been updated to include information about the effect that the H1N1 virus may have on the diagnosis and treatment of cancer treatment-related infections.
September 21, 2009
Article
A phase III trial demonstrated that denosumab can reduce fracture risk in men with nonmetastatic prostate cancer undergoing androgen deprivation therapy, Amgen announced.
September 21, 2009
Article
Avastin (bevacizumab) plus interferon-alfa has been approved for the treatment of metastatic renal cell carcinoma, according to Genentech. Approval was based on phase III data from the AVOREN study, which showed a 67% increase in progression-free survival (10.2 months) compared to those who received interferon-alfa alone (5.4 months; hazard ratio = 0.60).
September 21, 2009
Article
Exiqon Diagnostics has begun beta testing on the PortiQo Doctor Portal, which will allow oncologists to connect directly to the company.
September 21, 2009
Article
Breastfeeding reduces breast cancer risk among women with a family history of breast cancer, according to a study. Observational studies suggest a relationship between lactation and premenopausal breast cancer risk.
September 21, 2009
Article
Antioxidant supplements are not associated with an increased risk of melanoma, according to results from the Vitamins and Lifestyle study.
September 21, 2009
Article
Most melanomas are found during complete skin exams of patients who came to see a physician for different complaints, according to a study in the Archives of Dermatology.
September 21, 2009
Article
The FDA has accepted an Investigational New Drug (IND) application from CyDex Pharmaceuticals for a clinical study of Captisol-enabled melphalan HCL (CDX-353).
September 21, 2009
Article
Men with prostate cancer who consumed the active compounds in green tea demonstrated a significant reduction in serum markers predictive of prostate cancer progression, according to a study in Cancer Prevention Research (online June 19, 2009).
September 21, 2009
Article
Young men with advanced forms of prostate cancer do not live as long as older men with similar forms of the disease, according to research conducted at the University of Washington in Seattle.
September 21, 2009
Article
Metformin reduces an individual’s risk of developing pancreatic cancer by 62%, according to research from Houston’s M.D. Anderson Cancer Center. Metformin is the most commonly prescribed drug for patients with type 2 diabetes, who are often obese and/or have insulin resistance.
September 21, 2009
Article
TAMPA, Fla.-Genotyping could become a pivotal part of an individualized treatment program for cancer patients because some patients seem more susceptible to pain than others, according to research presented at the 2009 American Society of Preventive Oncology meeting.
September 21, 2009
Article
TORONTO-Two large, population-based studies with over 35 years of data revealed some of the factors that have influenced the incidence of thyroid cancer. Two key findings: Canadian men and people living in rural areas generally present with more advanced disease and the incidence of anaplastic thyroid cancer is waning. The studies were presented at the 2009 World Congress on Thyroid Cancer.
September 21, 2009
Article
Final results from a phase II study of an enhanced version of Herceptin upheld the emerging benefits previously seen with this novel approach in HER2-positive breast cancer.
September 21, 2009
Article
Current evidence does not support the routine use of breast MRI in women with newly diagnosed breast cancer, according to Monica Morrow, MD, chief of the breast service, department of surgery, at Memorial Sloan-Kettering Cancer Center.
September 21, 2009
Article
As a young candy striper at a Los Angeles hospital, lymphoma researcher Alexandra M. Levine, MD, MACP, experienced a portentous moment, although she didn’t necessarily realize it at the time. An older patient, feeling alone and lonely, waved the teenager to his bedside for a chat and she obliged. “He thanked me profusely for having helped him,” she said. “I didn’t understand what I had done, but it was one of those moments that was huge.”